Navigation Links
ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,,,Meeting

drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results for our CoFactor studies to differ materially include, but are not limited to: the validity of research results; uncertainties inherent in the drug development process; the timing and success of clinical trials; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.

CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,+1-858-552-0866; or Amy Martini of WeissComm Partners, +1-212-301-7223, forADVENTRX Pharmaceuticals, Inc.

Web site: http://www.adventrx.com/

Company News On-Call: http://www.prnewswire.com/gh/cnoc
'"/>




Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:7/24/2008)...EW YORK, July 24 /- MacroCh...nounced results of a Phase 2 clinical trial,involv...i-center,open-label efficacy and safety study of ...tment of onychomycosis (nail fungus). The composit...lete cure" defined as,negative mycology (negative ...
(Date:7/23/2008)...tudy results pending publication in July print edi...vailable on Web, INDIANAPOLIS, July 23 /PRNewswir...aluating the use of N-terminal pro-B-type natriure...ue of NT-proBNP for risk,stratification in predict...AE) in patients treated with non-steroidal anti-in...
(Date:7/23/2008)...OSTON, July 23 /- FluoroPharma Inc., ...g agents for the Positron Emission Tomography,(PET...FPET, its novel,Fluorine-18 labeled tracer for myo... second cardiovascular product to complete Phase I...ent, designed to assess the blood flow in the,hear...
(Date:7/23/2008)...EATTLE, July 23 /- Dendreon... it expects the Independent Data,Monitoring Commit...nalysis,of overall survival relating to the Compan...noCarcinoma Treatment, also known as D9902B) clini...is the Company,s investigational,active cellular i...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 1Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 2Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 3Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 4Stinger Systems Inc Settles With the SEC 3158 1Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 1Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 2Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 3Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 4Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 5057 1Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 5057 2
...ented at 2007 APA Meeting Also Showed No,Significa...COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstC... - one examining the,effect of desvenlafaxine succ... symptoms associated with major depressive disorde...hat examined the,effect of desvenlafaxine succinat...
...7 Percent Reduction in Risk of Hospitalization,fro...PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ --...alysis of a pivotal study,presented at the Digesti... showing patients with moderate to severely active...b) maintenance,therapy were almost 60 percent less...
Other Medicine Technology:Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
(Date:7/25/2008)...Robert J. Reilly, Joins Aethon Team, PITTSBURGH, ...ethon.com ), the leading developer of mobile robot...ounced that Robert J. Reilly has,joined the compan...cer., Reilly, who was most recently Vice Presiden...ecialty Pharmacy Division, brings more than 30,yea...
(Date:7/25/2008)...an cause immune system changes , , FRIDA...linking gastroesophageal reflux disease (GERD) and...ical Center researchers. , An association betwe..., and since then studies have shown that between 5...xperience GERD symptoms. But the actual link betwe...
(Date:7/25/2008)...mation Association (DIA) and the Food and Drug Adm...iative (CPI) on the Move: Complexities and Challen...cal Path Transporter Workshop (October 2-3; North ... PA (PRWEB) July 25, 2005-- The http://www.diahom...he Food and Drug Administration (FDA) will host th...
(Date:7/24/2008)...wswire/ -- Speaker Nancy Pelosi,released the follo...Lantos,and Henry J. Hyde Global Leadership Against...on Act of 2008. The bill, which passed the Senate ... of 303 to 115 and will now go,the President for h...historic vote to pass landmark legislation to,reau...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
... have come out with study results that encourage h...er of lymph nodes// marked by the presence of tu...ollow up. This, researchers opine, may be a defini... was shown to be positively associated with risks ...
...to experts, the Victorian disease tuberculosis is ...ction Agency of UK show// an increase by 2 percent...gures, released ahead of World TB Day, which falls...rovisional and relate to England, Wales and Northe...
...tudy finds that traditional Chinese medical belief...jing, China.// Jacqueline Hom, a dental student a...A, USA), reports her findings today during the 85t...ternational Association for Dental Research. Over...
...Health Organisation (WHO) has claimed that the glo...r the first time since it declared TB a public hea...Control Report released today, two days before the...of the world's population struck by TB peaked in 2...
Other Medicine News:Health News:Doctors Warned to Keep Track of Tumorous Lymph Nodes 2Health News:TB Cases on the Rise 2Health News:Global Tuberculosis Epidemic Levelling Off - WHO 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: